Gustavo Poblete co-authored this article with Christina Corridon, David Weil, and Tucker Herbert.
Biosimilar competition is disruptive and unpredictable: Not quite a true brand or a generic, it’s tough to predict what a biosimilar launch situation or go-to-market strategy will look like. We have examples to draw upon but no perfect analogues for each upcoming situation. It’s imperative to gather more customized insights related to a specific situation early to plan for varying biosimilar scenarios.
In this white paper, we discuss the risks of dragging your feet when it comes to preparing your biosimilar defense strategy, and how manufacturers can prepare to face the competition.